Xijing Hospital of digestive disease, Fourth Military Medical University
Welcome,         Profile    Billing    Logout  
 27 Trials 
25 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Han, Guohong
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Recruiting
3
480
RoW
Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatocellular Carcinoma
08/24
12/26
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
HAN
WU-KONG1, NCT03974022: Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer with EGFR or HER2 Mutation

Active, not recruiting
1/2
315
Europe, Canada, Japan, US, RoW
Sunvozertinib, DZD9008
Dizal Pharmaceuticals
Non-Small Cell Lung Cancer
07/24
07/25
SAT001-KP-003, NCT06742268: Extension Study on Safety and Rebound Effect of SAT-001 for Myopia in Children

Recruiting
N/A
40
RoW
Single vision spectacles
S-Alpha Therapeutics, Inc.
Myopia
10/25
07/26
Chen, Hui
NCT04683406: A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

Completed
3
750
RoW
ZSP1273 600 mg, Placebo to Oseltamivir, Oseltamivir(oral), Placebo to ZSP1273
Guangdong Raynovent Biotech Co., Ltd
Influenza A
04/23
05/23
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
496
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
NCT01024530: Phase II/III Trial of Hepatocellular Carcinoma Patients Treated by ex Vivo Expanded Autologous Immune Killer Cells as the Adjunct Therapy

Recruiting
2/3
60
RoW
immune killer cells (IKC)
Shin Kong Wu Ho-Su Memorial Hospital, Ivy Life Sciences, Co., Ltd
Hepatocellular Carcinoma, Liver Cancer
05/12
 
CYCLONE 2, NCT03706365 / 2016-004276-21: A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

Active, not recruiting
2/3
350
Europe, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone Acetate, Prednisone, Placebo
Eli Lilly and Company
Prostate Cancer
01/24
06/26
MRG002-006, NCT04839510: A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Recruiting
2
58
RoW
MRG002
Shanghai Miracogen Inc.
Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
06/22
09/22
NCT04426968: A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B

Completed
2
96
RoW
Hepalatide 2.1mg, L47, Hepalatide 4.2mg, Hepalatide 6.3mg, placebo 2.1mg, placebo 4.2mg, placebo 6.3mg, Pegylated Interferon, Pegasys
Shanghai HEP Pharmaceutical Co., Ltd.
Hepatitis B, Chronic
11/23
11/23
NCT04492293: An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

Recruiting
2
115
RoW
ICP-192
Beijing InnoCare Pharma Tech Co., Ltd.
Bladder Urothelial Cancer
12/24
06/25
NCT05763199: Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy

Recruiting
2
20
US
AHCC, A standardized extract of cultured Lentinula edodes mycelia, Chemotherapy, Placebo
University of California, Davis, Amino Up Chemicals Co., Ltd., National Cancer Institute (NCI)
Ovarian Epithelial Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
04/26
07/27
NCT05405439: To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

Terminated
1/2
39
RoW
TQB3823 tablets, Abiraterone acetate tablets, prednisone acetate tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Castration-resistant Prostate Cancer
07/23
07/23
IMC-C103C-101, NCT03973333: Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Withdrawn
1/2
75
Europe, US
IMC-C103C, Atezolizumab, TECENTRIQ
Immunocore Ltd
Select Advanced Solid Tumors
09/23
09/23
IMC-F106C-101, NCT04262466 / 2019-004046-16: Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Hourglass Oct 2024 - Dec 2024 : Data for late-line NSCLC
Recruiting
1/2
727
Europe, Canada, US, RoW
Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors
Immunocore Ltd
Select Advanced Solid Tumors
02/26
08/26
NCT06452693: A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B

Not yet recruiting
1/2
162
RoW
TQA3038 injection/placebo, Nucleotide drugs Control group
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatitis B, Chronic
09/26
09/26
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
NCT06186414: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

Recruiting
1
152
RoW
SIM0237, SIM0237 and BCG
Jiangsu Simcere Pharmaceutical Co., Ltd., Shanghai Xianxiang Medical Technology Co., Ltd.
Non-Muscle-Invasive Bladder Cancer (NMIBC)
01/27
12/30
NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

Recruiting
1
153
RoW
HRS-1167
Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
12/24
12/24
NCT04953117: A Safety and Efficacy Study of Lepu® Drug Coated Balloon in Treatment of Coronary Small-vessel Disease

Recruiting
N/A
286
RoW
DCB of Lepu Medical(dimeter≥2.00 mm), Coronary Drug Coated Balloon Catheter of Lepu Medical for coronary small vessels, Restore DEB, RESTORE Paclitaxel releasing coronary balloon catheter, DCB of Lepu Medical(dimeter<2.00 mm), Coronary Drug Coated Balloon Catheter of Lepu Medical for coronary very small vessels
Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease
06/22
04/23
NCT05755776: The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment

Recruiting
N/A
204
RoW
TMF, Heng Mu
The Second Affiliated Hospital of Chongqing Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Chronic Hepatitis B
12/24
12/24
Lv, Yong
No trials found

Download Options